[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-disorders":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,88,119,139],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100583058","dietary-strategy-to-tackle-cognitive-and-locomotor-abilities-in-early-elderly-subjects-100583058",false,"NCT06871384","Dietary Strategy to Tackle Cognitive and Locomotor Abilities in Early Elderly Subjects","Polyphenols From Nonalcoholic Red Wine and Healthy Aging: an Opportunity to Understand Diet Modulation of the Aging Process From a Multidimensional Perspective","WinAging","Inclusion Criteria:\n\n1\\. Men or women between 60-74 years old; Sensory tolerance to red wine; Written informed consent provided before the initial screening visit.\n\nExclusion Criteria:\n\n1. Men or women \\>75 years old,\n2. Hypoglucaemiant treatment or type 1 and type 2 diabetes mellitus diagnosed\n3. Anaemia (hemoglobin ≤13 g\u002FdL in men and ≤12 g\u002FdL in women)\n4. Subjects diagnosed of intestinal disorders such as chron disease, colitis ulcerous, and irritable bowel syndrome\n5. To present a clinical active chronic disease\n6. To present severe sarcopenia\n7. To present cognitive impairment (MMSE ≤ 24 or clinical diagnosis of mild cognitive impairment or dementia)\n8. Dietary allergies to: Mediterranean foods (eg, nuts), sulphytes or nitrates\n9. Use of antioxidants supplements\n10. Regular consumers of red wine who do not agree to change the consumption of red wine with alcohol to nonalcholized wine during the intervention\n11. Chronic alcoholism\n12. Current or past participation in a clinical trial or consumption of a research product in the 30 days prior to inclusion in the study\n13. Failure to follow the study guidelines. For participation in the muscle biopsy, additional exclusion criteria included: Use of prescription anti-platelet medication; Prescription anticoagulant use (or antiaggregant, or acenocoumarol; Conditions which would reduce healing; or known allergy to lidocaine.",true,"ALL","60 Years","74 Years",{"count":22,"type":23},72,"ESTIMATED","INTERVENTIONAL",[26],"NA","Polyphenols, precisely resveratrol, with red wine as the most substantial source, was associated with improvements in cognitive function. Also, the loss of muscle mass and strength in elderly, that significantly increases dependency of these people, it could be attributed to alterations in gut microbiota through the \"gut-muscle axis\" and this underline the urgent need to efficiently find out any intervention or preventive approach via modulation of gut microbiota to improve muscle function in elderly. In this context, red wine polyphenols exert their effects through interaction with gut microbiota following the well-known two-way interaction between polyphenols and gut microbiota by promoting the proliferation of beneficial bacteria and increasing their abundance. Similarly, aging cognitive decline can be modulate by microbiota, notably through \"gut-brain axis\". Additionally, dietary polyphenols can delay inflammation or\u002Fand oxidation on the onset of age-related cognitive decline or muscular oxidation or cardiovascular factors risk factors, all of them relevant factors for the onset of physical frailty and dependence in elderly.\n\nMoreover, wine is a singular alcoholic beverage with a high content of phenolic compounds of a very diverse nature on which numerous protective effects on health have been described. In fact, wine, in addition to alcohol, contains a complex mixture of polyphenols, including anthocyanins and non-coloured phenols as proanthocyanidins, flavonols, hydroxycinnamic and hydroxybenzoic acids, stilbenes and lignans. Thus, the bioprotective effects of wine polyphenols could be the consequence of the synergistic effect of this complex mixture of polyphenols from the grape and the winemaking process. That is why it is essential to clarify whether consumption of polyphenols from red wine provided by a nonalcohol red wine within a healthy diet can produce beneficial effects on health, differentiating this pattern from a general consumption of alcohol generally associated with negative effects. Based on the ethical limitations to carry out diet intervention studies with wine in humans, this project proposes the use of a nonalcoholic wine as vehicle of the complex mixture of red wine polyphenols.\n\nThe hypothesis of our research is that regular consumption of red wine polyphenols, 150 mg\u002Fday, delivered through a nonalcoholic red wine, in the context of a Mediterranean diet (MD pattern), could promote protective mechanisms for a healthy aging, especially through its beneficial effects on cognitive and locomotor abilities and mediated by the modulation of the intestinal microbiota (composition, function and associated metabolome). The main objective of the WinAging project is to add knowledge concerning the diet modulation of molecular mechanisms of the aging process through multi-omic approaches based on the potential health effects of a dietary strategy by a sustained MD supplementation with nonalcoholic red wine rich in polyphenols to tackle cognitive and locomotor abilities in early elderly home-dwelling subjects.\n\nThe specific objectives:\n\n* Objective 1. To develop a nonalcoholic red wine with high phenolic content and sensorial acceptability.\n* Objective 2. To evaluate the chronic effects of the intake of wine polyphenols (average dose 150 mg\u002Fday) delivered through a nonalcoholic red wine in the context of a MD in early elderly home-dwelling subjects, and applying participatory research to increase adherence of subjects in the clinical intervention study.\n\n  * Objective 2.1. To identify selective biological phenolic metabolites in human urine samples to be used as biomarkers of nonalcoholic red wine intake.\n  * Objective 2.2. To assess the effects of the diet supplementation with red wine polyphenols on the improvement of cognitive ability.\n  * Objective 2.3. To assess the effects of the diet supplementation with red wine polyphenols on the improvement of locomotor ability\n  * Objective 2.4. To evaluate the effect of the diet supplementation with red wine polyphenols on the improvement of cardiovascular disease (CVD) risk factors.\n* Objective 3. To unravel the underlying mechanisms involved in the potential beneficial effects of red wine polyphenols on aging.\n\n  * Objective 3.1. To evaluate the influence on microbiota composition, function and microbial catabolites.\n  * Objective 3.2. To evaluate the impact on inflammation and gut health.\n  * Objective 3.3. To evaluate the impact on metabolic pathways related with aging\n  * Objective 3.4. To analyze the impact on age-related epigenetic modifications\n  * Objective 3.5. To deeply characterize the underlying muscle signalling pathways affected using an animal model of aging.\n* Objective 4. To apply integrative computational analyses for the identification of variables (clinical or gut-related) more determinant for a successful prevention of locomotor and cognitive abilities associated with wine polyphenols.",[29,30],"Cognitive Disorders","Muscular Disorders, Atrophic",[32,33,34,35,36,37,38],"cognitive impairment","locomotor impairment","sarcopenia","aging","mediterrnean diet","non-alcoholic wine","polyphenols","RECRUITING","2026-03-03",{"date":42,"type":43},"2026-03-05","ACTUAL",{"date":45,"type":43},"2025-03-26",{"date":47,"type":23},"2027-04",{"name":49,"class":50},"University Rovira i Virgili","OTHER",3,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":17,"sex":18,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":4},"100622787","neuroinflammatory-biomarkers-after-general-anesthesia-a-comparison-study-100622787","NCT07388160","Neuroinflammatory Biomarkers After General Anesthesia: A Comparison Study","Evaluation of Preoperative and Postoperative Serum BDNF, IL-1β, and HMGB1 Levels and Cognitive Changes in Patients Undergoing General Anesthesia: Differences Between Patients With No Prior General Anesthesia and Those With Multiple Anesthesia Exposures","Inclusion Criteria:\n\n* Age 18-65 years\n* Scheduled for elective cholecystectomy surgery\n* Either no previous general anesthesia exposure OR at least one or more previous general anesthesia exposures\n* Ability to provide informed consent\n* American Society of Anesthesiologists (ASA) physical status I-II\n\nExclusion Criteria:\n\n* Chronic neurological diseases (Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc.)\n* Psychiatric illness requiring medication\n* Metabolic syndrome (diabetes mellitus, hypertension, cardiac disease)\n* Chronic inflammatory diseases (rheumatoid arthritis, systemic lupus erythematosus, etc.)\n* Corticosteroid or immunosuppressive therapy within the last 6 months\n* Patients requiring intensive care admission\n* Pregnancy or breastfeeding\n* Known allergy to anesthetic agents\n* Inability to provide informed consent","18 Years","65 Years",{"count":62,"type":23},160,"OBSERVATIONAL","This prospective, observational study investigates the impact of repeated general anesthesia exposure on neuroinflammatory biomarkers and neurotrophic factors. The study will enroll 160 adult patients (aged 18-65 years) scheduled for elective cholecystectomy surgery, divided into two groups: patients with no previous general anesthesia exposure (n=80) and patients with at least one or more previous general anesthesia exposures (n=80).\n\nSerum levels of Brain-Derived Neurotrophic Factor (BDNF), Interleukin-1 beta (IL-1β), and High Mobility Group Box 1 (HMGB1) will be measured using ELISA method at two time points: preoperatively (baseline) and 24 hours postoperatively. Cognitive function will also be assessed at both time points.\n\nThe primary objective is to evaluate whether multiple exposures to general anesthesia lead to significant differences in serum BDNF, IL-1β, and HMGB1 levels, reflecting changes in neurotrophic balance and neuroinflammatory response. This study aims to provide insights into the potential biochemical mechanisms underlying anesthesia-related cognitive changes and contribute original clinical data to the current literature on general anesthesia safety and neurobiological effects.",[66,67,29],"Anesthesia","Neuroinflammation",[69,70,71,67,72,73,74,75,76],"Brain Derived Neurotrophic Factor","Interleukin-1 beta","General Anesthesia","Cognitive Dysfunction","Biomarkers","Sevofluran","Inflammatory Cytokines","Anesthesia Neurotoxicity","NOT_YET_RECRUITING","2026-01-30",{"date":80,"type":43},"2026-02-04",{"date":82,"type":23},"2026-01-25",{"date":84,"type":23},"2026-09-25",{"name":86,"class":87},"University of Health Sciences Balikesir Hospital Eduation and Research","OTHER_GOV",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":96,"minAge":4,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":24,"phases":99,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":118},"100592593","breast-cancer-and-chemobrain--effects-of-photobiomodulation-on-the-improvement-of-perceived-cognitive-impairment-100592593","NCT06995443","Breast Cancer and Chemobrain : Effects of Photobiomodulation on the Improvement of Perceived Cognitive Impairment","Breast Cancer and Chemobrain : Effects of Photobiomodulation on the Improvement of Perceived Cognitive Impairment - REGAIN","REGAIN","Inclusion Criteria:\n\n* Women aged 18 and over\n* Having completed chemotherapy (intravenous) for breast cancer (any stage) less than 12 months prior to inclusion\n* Having a perceived cognitive complaint that appeared during or after (\\\u003C 3 months) chemotherapy treatments (no restriction on the care protocol used) and confirmed by a FACT-Cog score compatible with a subjective cognitive disorder (score \\\u003C 117 for patients aged 18 to 49; score \\\u003C 113 for patients aged 50 to 69; score \\\u003C105 for patients aged 70 and over)\n* Patient eligible for photobiomodulation sessions\n* Patient with sufficient command of the French language to complete the study questionnaries\n* Patient having given written consent to participate in the trial\n* Socially insured patient\n* Patient willing to comply with all study procedures and duration\n\nExclusion Criteria:\n\n* Known cognitive disorders prior to chemotherapy treatment\n* Patients with psychiatric or psychobehavioral disorders incompatible with photobiomodulation sessions\n* Patients who, in the 12 months prior to inclusion or at the time of inclusion, have already received photobiomodulation treatment involving \"whole body\" therapy (photobiomodulation in a phototherapy booth).\n* Patient having previously received photobiomodulation with cortical stimulation (panel or helmet) with no time limit.\n* Patient taking or having received capecitabine\n* Patients taking part in a protocol involving a drug likely to affect cognitive performance (on the investigator's advice).\n* Patients suffering from claustrophobia\n* Patient unable to read and\u002For unable to complete a questionnaire, in the opinion of the investigator","FEMALE",{"count":98,"type":23},200,[26],"Breast cancer is one of the most common cancers in metropolitan France, with over 60,000 new cases in 2023. Mostly a female cancer, it can affect a young population, with around 20% of breast cancers occurring in women under 50. Treatment is mainly based on surgery, chemotherapy, radiotherapy, targeted therapies and hormone therapy. Although chemotherapy is not systematically used, it remains a frequent treatment option. While chemotherapy makes a major contribution to curing cancer, it is also a source of potentially disabling side effects for survivors.\n\nChemotherapy can interfere with the normal functioning of the central nervous system, leading to cognitive impairment. The number of people potentially affected by chemobrain is estimated at several tens of millions worldwide. There is no recommended treatment for people with chemobrain. Several avenues have been explored, with very limited results. Photobiomodulation (PBM) is a non-medicinal treatment technique that combines all the biological, athermic and non-cytotoxic effects of tissue exposure to non-ionizing sources of red and infrared light. Several studies have demonstrated the beneficial effects of cortical stimulation by photobiomodulation on memory (increased angiogenesis, increased oxygenation of brain tissue via vasodilatation, and increased mitochondrial ATP production). These positive biological effects are likely to ameliorate the undesirable effects of chemotherapy, and consequently the post-chemotherapy cognitive disorders that ensue.",[102,103,29],"Oncology","Support Care",[105,106,107,108],"Cognitive disorders","Photobiomodulation","Breast cancer","oncology","2026-01-29",{"date":78,"type":43},{"date":112,"type":43},"2025-06-13",{"date":114,"type":23},"2027-12",{"name":116,"class":117},"Centre Hospitalier de Valenciennes","NETWORK",1,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":17,"sex":18,"minAge":59,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":24,"phases":127,"briefSummary":128,"conditions":129,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":118},"100507559","single-center-prospective-longitudinal-study-of-taste-in-patients-with-cognitive-disorders-at-different-stages-of-severity-isolated-cognitive-complaint-minor-or-major-neurocognitive-alzheimer-type-disorders-by-analysis-of-gustatory-evoked-potentials-100507559","NCT05888961","Single-center Prospective Longitudinal Study of Taste in Patients With Cognitive Disorders at Different Stages of Severity (Isolated Cognitive Complaint, Minor or Major Neurocognitive Alzheimer-type Disorders) by Analysis of Gustatory Evoked Potentials","MAPEG 2","Inclusion Criteria:\n\n* Person who has given oral consent.\n* For patients with mild to moderate Alzheimer\\'s disease, the primary caregiver and the patient will be asked to provide oral consent\n* Person of legal age\n* Body Mass Index (BMI) \\< 30 kg\u002Fm².\n* For the healthy group: absence of cognitive complaints and normal neurological assessment\n* Patients meeting the criteria for isolated cognitive complaint: presence of cognitive complaint but normal neuropsychological evaluation\n* Patients meeting diagnostic criteria for minor cognitive impairment: imaging (brain MRI) and neuropsychological assessment with a Clinical Dementia Rating (CDR) score of 0.5\n* Patients meeting diagnostic criteria for mild to moderate Alzheimer\\'s disease: imaging (brain MRI), neuropsychobiological criteria (consultation with neuropsychological assessment, CSF biomarkers), MMSE score ≥ 20 and CDR score of 1 or 1.5\n* Fasting for at least 2 hours before GEP measurement\n\nExclusion Criteria:\n\n* MMSE score\\<15\n* Known COVID-19 infection within 6 months prior to inclusion\n* Person not affiliated to national health insurance system\n* Person under a legal protection measure (curatorship, guardianship)\n* Person subject to a measure of legal protection\n* Pregnant, parturient or breastfeeding women\n* Subjects with a pacemaker (contraindication to bioelectrical impedance measurement)\n* Adult unable to express consent or to perform cognitive tests.\n* Active smoker (\\> 4 cigarettes per day on a regular basis)\n* Diabetic subject (type 1 or type 2)\n* Subject with acute or chronic ENT disease\n* Treatment interfering with gustation\n* Brain MRI showing another cause of neurocognitive disorder (except for vascular lesions Fazekas 1 accepted)",{"count":22,"type":23},[26],"The aim of the MAPEG 2 study is to explore gustatory function and to follow its evolution in the 4 following groups of participants:\n\n* Healthy subjects\n* Participants with isolated cognitive complaint\n* Participants with minor neurocognitive disorder\n* Participants with mild and moderate Alzheimer-type major neurocognitive disorders\n\nFor this purpose, we want to compare the results of the following tests:\n\n* Subjective taste tests (tasting solutions, answering food preference questionnaires),\n* Gustatory evoked potential (GEP) parameters, recorded by electrodes placed on the scalp,\n* And nutritional parameters (hormones of food intake by blood test, measurement of the global body composition).\n\nIdentifying and following the evolution of early taste disorders in case of cognitive disorders could improve the diagnosis of Alzheimer\\'s disease in two ways:\n\n* To allow an early diagnosis of Alzheimer\\'s disease, and thus improve its management,\n* To define groups of subjects at risk of developing Alzheimer\\'s disease in later years.",[29],"2025-07-08",{"date":132,"type":43},"2025-07-11",{"date":134,"type":43},"2023-06-12",{"date":136,"type":23},"2027-07",{"name":138,"class":50},"Centre Hospitalier Universitaire Dijon",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":18,"minAge":59,"maxAge":60,"enrollmentInfo":146,"targetDuration":4,"studyType":24,"phases":148,"briefSummary":149,"conditions":150,"keywords":154,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":118},"100590220","cognitive-rehabilitation-of-deficits-in-patients-with-multiple-sclerosis-100590220","NCT06964581","Cognitive Rehabilitation of Deficits in Patients With Multiple Sclerosis","Cognitive Rehabilitation of Deficits in Patients With Multiple Sclerosis: Proposal for an Integrated Cognitive Treatment in a Telematic Format","Inclusion Criteria:\n\n* Diagnosis of relapsing-remitting multiple sclerosis (RRMS), or primary progressive (PPMS) or secondary progressive (SPMS), defined by at least 3-6 months.\n* Age between 18 and 65 years.\n* Expanded Disability Status Scale (EDSS) between 3 and 5 to include patients with overall neurological disability from mild to moderate.\n* Presence of one or more of the following cognitive disorders (reported by the patient and subsequently confirmed through the Oxford Cognitive Screen-OCS):\n* Memory disorders\n* Attention disorders\n* Executive function disorders\n* Availability of internet at the patient's home necessary for the tele-rehabilitation procedures.\n* Adequate visual and auditory abilities to use the rehabilitation device.\n\nExclusion Criteria:\n\n* Presence of other neurological conditions;\n* Psychiatric disorders in medical history;\n* Alcohol and\u002For drug abuse;\n* Presence of uncorrected severe visual deficits.",{"count":147,"type":23},60,[26],"Non-Inferiority Study, Post-Market Clinical Investigation with a Device, Single-Blind Randomized Controlled Trial in a Cohort of Patients Diagnosed with Multiple Sclerosis (MS).\n\nThe aim of the study is to assess whether a computer-based cognitive treatment delivered via telerehabilitation produces effects from T0 to T1 that are not inferior to those of an in-person treatment on sustained attention in a cohort of patients with MS.\n\nThe secondary objective is to evaluate the effects of telerehabilitation compared to the same treatment delivered in person on attentional shifting, memory, executive functions, and daily functioning (including cognitive fatigue, quality of life, and mood) in patients with MS.",[151,152,29,153],"Telerehabilitation","Multiple Sclerosis","Neurorehabilitation",[155,156,157],"telerehabilitation","multiple sclerosis","cognitive disorders","2025-04-30",{"date":160,"type":43},"2025-05-09",{"date":162,"type":43},"2023-02-08",{"date":164,"type":23},"2025-09-30",{"name":166,"class":50},"Universita di Verona"]